Literature DB >> 11896599

Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice.

Pedro Antonio Pérez-Mancera1, Jesus Pérez-Losada, Manuel Sánchez-Martín, Maria Aranzazu Rodríguez-García, Teresa Flores, Enrique Battaner, Alfonso Gutiérrez-Adán, Belen Pintado, Isidro Sánchez-García.   

Abstract

Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS-CHOP fusion gene. In the past, we generated FUS-CHOP and CHOP transgenic mice and have shown that while FUS-CHOP transgenic develop liposarcomas, mice expressing CHOP, which lacks the FUS domain, display essentially normal white adipose tissue (WAT) development, suggesting that the FUS domain of FUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma. To test the significance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOP-transgenic mice to generate double-transgenic FUSxCHOP animals. Here we report that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma. These results identify a new mechanism of tumor-associated fusion genes and might have impact beyond myxoid liposarcoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896599     DOI: 10.1038/sj.onc.1205220

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  Animal models of soft-tissue sarcoma.

Authors:  Rebecca D Dodd; Jeffery K Mito; David G Kirsch
Journal:  Dis Model Mech       Date:  2010-08-16       Impact factor: 5.758

3.  FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.

Authors:  Pedro A Pérez-Mancera; Camino Bermejo-Rodríguez; Manuel Sánchez-Martín; Fernando Abollo-Jiménez; Belén Pintado; Isidro Sánchez-García
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

4.  The Fusion Oncogene FUS-CHOP Drives Sarcomagenesis of High-Grade Spindle Cell Sarcomas in Mice.

Authors:  Mark Chen; Eric S Xu; Nathan H Leisenring; Diana M Cardona; Lixia Luo; Yan Ma; Andrea Ventura; David G Kirsch
Journal:  Sarcoma       Date:  2019-07-25

5.  A unified mechanism for LLPS of ALS/FTLD-causing FUS as well as its modulation by ATP and oligonucleic acids.

Authors:  Jian Kang; Liangzhong Lim; Yimei Lu; Jianxing Song
Journal:  PLoS Biol       Date:  2019-06-12       Impact factor: 8.029

6.  Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.

Authors:  Lauren T Kerr; Jacqueline F Donoghue; Alexander L Wilding; Terrance G Johns
Journal:  Sarcoma       Date:  2016-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.